NCT06075927 2023-10-10
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
Peking University People's Hospital
Phase 1/2 Unknown
Clinical Trials
9 trialsNCT04507477 2022-08-02
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
University Health Network, Toronto
Phase 1/2 Unknown
NCT04084626 2022-01-05
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Beijing Friendship Hospital
Phase 3 Unknown
NCT05039580 2021-09-09
SEHC
The First Affiliated Hospital of Soochow University
Phase 4 Unknown
NCT04690036 2021-06-29
PD-1 Antibody for Reactive EBV After BMT
Beijing Friendship Hospital
Phase EARLY_PHASE1 Unknown
NCT03159364 2019-09-19
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT02912702 2016-09-23
L-DEP as an Initial Treatment for EBV-HLH
Beijing Friendship Hospital
Phase 3 Unknown
NCT02631109 2016-08-04
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Beijing Friendship Hospital
Phase 3 Unknown
NCT02761291 2016-05-16
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
Chang Gung Memorial Hospital
Phase 1 Unknown